PPRS scheme payment percentage to rise by 6.62% in 2015
December 12, 2014Sales and Marketing ABPI, PPRS, VBP, Whitehead, government, medicines bill
The amount of payment due from pharma via the PPRS scheme for next year has been confirmed by the Department …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Unilife appoints comms VP from Intel
December 12, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing kevin sellers, unilife
US developer of injectable drugs Unilife has looked to Intel to appoint a marketing and communications veteran in Kevin Sellers. …
Antibiotic resistance could kill 10 million a year
December 11, 2014Research and Development, Sales and Marketing Antibiotics, Cancer, KPMG, Merck, david cameron, rand
Antibiotic-resistant bacteria will kill an extra 10 million people a year by 2050 if the problem is not tackled soon, …
Sanofi looking to diversify, may buy into animal health
December 11, 2014Manufacturing and Production, Research and Development, Sales and Marketing EFPIA, Jimenez, Sanofi, Serge Weinberg, Viehbacher, animal health
Sanofi is looking to diversify and is even considering buying into the consumer and animal health markets according to its …
Takeda eyes new drug licences following positive blood cancer studies
December 11, 2014Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology
Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …
Boehringer trials Pradaxa anti-bleeding antidote
December 11, 2014Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab
Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …
Mylan shells out $32.5m to cover tax inversion fines
December 11, 2014Sales and Marketing AbbVie, Abbott, Mylan, SEC, bresch, coury
Mylan will pay five of its top executives an early $32.5 million to cover penalties from the company’s plans to …
Tamoxifen found to reduce breast cancer rates by 30%
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Arimidex, NICE, anastrozole, astrazenea, breast cancer, tamoxifen
A study from Queen Mary University has demonstrated that tamoxifen can reduce breast cancer rates by around 30% over 20 …
Half of England on prescription drugs
December 11, 2014Sales and Marketing England, HSCIC, NHS, doctors, prescribing, prescriptions
Almost half of the people in England are taking regular prescription medicines according to a new report by the Health …
Kim Lemon named head of Liberation Unlimited
December 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Creston Health, kim lemon, liberation unlimited
Marketing communications agency Liberation Unlimited has appointed Kim Lemon to head its operations. Since the UK-based comms firm joined the …
Treatment shifts away from chemotherapy for multiple myeloma
December 10, 2014Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals
Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …
Private firms account for a third of NHS contracts
December 10, 2014Medical Communications, Sales and Marketing Budget, Cameron, Hunt, NHS, Osborne, autumn, election, privatisation
A large percentage of NHS contracts in England have been awarded to private sector providers since 2013, according to data …
Labour to extend cancer drugs funding if elected
December 10, 2014Research and Development, Sales and Marketing CDF, Cancer, Labour, NHS, NICE, andy burnham, election
Labour has committed to continuing the Cancer Drugs Fund system under the guise of a new £330 million ‘Cancer Treatment …
EFPIA gives president role to Novartis chief executive
December 10, 2014Medical Communications, Sales and Marketing EFPIA, Novartis, Sanofi, Witty, garidel, joe jimenez, oschmann
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has named Novartis chief executive Joe Jimenez as its new president. …
Pharnext adds industry veteran to board
December 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michel de Rosen, pharnext
France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …
AstraZeneca constipation drug gets EU nod
December 9, 2014Sales and Marketing AstraZeneca, KODIAC, NKTR-118, PAMORA, moventig, naloxegol
AstraZeneca’s opioid-induced constipation drug Moventig has been approved by the European Commission. The first once-daily PAMORA tablet to be given …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Mixed results for new leukaemia drugs
December 9, 2014Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib
Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …
Novartis biosimilar rivals Amgen offering
December 9, 2014Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, filgrastim, zarzio
An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
